CORE--CELL LINE AND ANIMAL TESTING

核心——细胞系和动物测试

• 批准号: 6650588
• 负责人: GARTH POWIS
• 金额: $ 25.04万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-05-01 至 2003-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6650588
• 关键词: MCF7 cell; SCID mouse; antineoplastics; biomedical facility; cell line; cooperative study; disease /disorder model; drug screening /evaluation; growth inhibitors; neoplasm /cancer transplantation; neoplastic cell; pharmacokinetics

Description: (Applicant's Description) The objective of the Cell Line and Animal Testing Core Service D is to use state-of-the-art in vitro cell culture techniques and in vivo animal tumor models to successfully identify potential new anticancer agents from lead compounds produced by the NCDDG. The underlying hypothesis upon which work by the core service is based is that data obtained by in vitro screening with human tumor cell lines and in animal tumor models has predictive value for detennining which agents will be effective against cancers in humans. The aims of the core service are: 1) to identify compounds having significant growth inhibitory activity against a panel of human tumor cell lines in culture; 2) to conduct in vivo testing of selected compounds using the hollow fiber assay in scid mice; 3) to conduct in vivo testing against early stage human tumor xenografts in scid mice; and, 4) to conduct in vivo testing and route and scheduling studies against advanced human tumor xenografts in scid mice. Selection criteria for advancing compounds through the testing process have been identified. The ultimate goal of the core service to identify from among the lead compounds and analogues synthesized by the NCDDG candidate drugs for preclinical development and eventual clinical trial as anticancer agents.

描述：（申请人的描述） 细胞系和动物测试核心服务的目的是使用 最先进的体外细胞培养技术和体内动物肿瘤 成功识别潜在潜在的新抗癌剂的模型 NCDDG产生的化合物。起作用的基本假设 核心服务的基于 人类肿瘤细胞系和动物肿瘤模型具有预测价值 确定哪些代理人将对人类的癌症有效。这 核心服务的目的是：1）识别具有重要意义的化合物 针对人类肿瘤细胞系的生长抑制活性 文化; 2）使用空心进行所选化合物的体内测试 SCID小鼠中的纤维测定； 3）在早期进行体内测试 SCID小鼠中的人类肿瘤异种移植物； 4）进行体内测试和 SCID中针对晚期人类肿瘤异种移植的路线和调度研究 老鼠。通过测试过程推进化合物的选择标准 已经确定了。核心服务的最终目标是从 在NCDDG候选者合成的铅化合物和类似物中 临床前开发和最终临床试验的药物作为抗癌药 代理商。